191 related articles for article (PubMed ID: 19691126)
21. Inhibition of levodopa effects by internal pallidal stimulation.
Krack P; Pollak P; Limousin P; Hoffmann D; Benazzouz A; Benabid AL
Mov Disord; 1998 Jul; 13(4):648-52. PubMed ID: 9686769
[TBL] [Abstract][Full Text] [Related]
22. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
23. Intra- and inter-limb coherency during stance in non-dyskinetic and dyskinetic patients with Parkinson's disease.
Mann RK; Edwards R; Zhou J; Jog M; Duval C
Clin Neurol Neurosurg; 2010 Jun; 112(5):392-9. PubMed ID: 20206438
[TBL] [Abstract][Full Text] [Related]
24. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.
Filipović SR; Rothwell JC; van de Warrenburg BP; Bhatia K
Mov Disord; 2009 Jan; 24(2):246-53. PubMed ID: 18951540
[TBL] [Abstract][Full Text] [Related]
25. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
26. [Physiopathology of the dyskinesias induced by L-dopa].
Grandas F; López-Ariztegui N
Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
[TBL] [Abstract][Full Text] [Related]
27. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease.
Yamada K; Goto S; Hamasaki T; Kuratsu JI
Acta Neurochir (Wien); 2008 Jan; 150(1):15-22; discussion 22. PubMed ID: 18180867
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal study of the motor response to levodopa in Parkinson's disease.
Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
[TBL] [Abstract][Full Text] [Related]
29. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
Alonso-Frech F; Zamarbide I; Alegre M; Rodríguez-Oroz MC; Guridi J; Manrique M; Valencia M; Artieda J; Obeso JA
Brain; 2006 Jul; 129(Pt 7):1748-57. PubMed ID: 16684788
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease.
Gomez Arevalo G; Jorge R; Garcia S; Scipioni O; Gershanik O
Mov Disord; 1997 May; 12(3):277-84. PubMed ID: 9159719
[TBL] [Abstract][Full Text] [Related]
31. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
Suh DC; Pahwa R; Mallya U
J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
[TBL] [Abstract][Full Text] [Related]
32. Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease.
Brusa L; Versace V; Koch G; Iani C; Stanzione P; Bernardi G; Centonze D
Clin Neurophysiol; 2006 Sep; 117(9):1917-21. PubMed ID: 16887383
[TBL] [Abstract][Full Text] [Related]
33. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
34. Neither simple nor sequential arm movements are bradykinetic in parkinsonian patients with peak-dose dyskinesias.
Agostino R; Bagnato S; Dinapoli L; Modugno N; Berardelli A
Clin Neurophysiol; 2005 Sep; 116(9):2077-82. PubMed ID: 16055379
[TBL] [Abstract][Full Text] [Related]
35. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
36. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
37. [Motor complications in patients with Parkinson disease treated with levodopa].
Luquin MR; Obeso JA; Martínez-Lage JM
Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806
[TBL] [Abstract][Full Text] [Related]
38. Parkinson's disease: progression and mortality in the L-DOPA era.
Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
[No Abstract] [Full Text] [Related]
39. Grip force abnormalities in de novo Parkinson's disease.
Fellows SJ; Noth J
Mov Disord; 2004 May; 19(5):560-5. PubMed ID: 15133821
[TBL] [Abstract][Full Text] [Related]
40. Current controversies: levodopa in the treatment of Parkinson's disease.
Sharma JC; Vassallo M; Ross IN
Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
